News

September 11, 2019

Largest-ever African American Prostate Cancer Study Seeks Participants

News

African American men recently diagnosed with prostate cancer are being recruited across the U.S. for the largest-ever prostate cancer study in this ethnic group. The study is a joint effort by ... Read more

September 9, 2019September 24, 2019

Provenge Extends Survival of mCRPC Patients By Up to 4 Years, Data Show

News

Treatment with the immunotherapy Provenge (sipuleucel-T) in a real-world setting is showing similar safety and efficacy in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) as in ... Read more

September 5, 2019

Collaborators Work to Develop New Sequencing Methods to Manage Cancers

News

The nonprofit organization Genome Canada, the pharmaceutical company Thermo Fisher Scientific and the Ontario Institute for Cancer Research (OICR) are collaborating to develop new targeted next generation sequencing (NGS) methods ... Read more

September 4, 2019

Add-on Onvansertib Overcomes Resistance to Zytiga in mCRPC, Early Data Show

News

Adding the investigational oral therapy onvansertib to a regimen of Zytiga (abiraterone acetate) and prednisone overcomes resistance to Zytiga in men with metastatic castration-resistant prostate cancer (mCRPC), according to early ... Read more

August 29, 2019

FDA Clears Way for Trial of Immunotherapy in Advanced Prostate Cancer, Scripps Research Says

News

The U.S. Food and Drug Administration (FDA) has signed off on a clinical trial that will test CCW702, an immunotherapy developed by Calibr at Scripps Research, as a possible treatment of ... Read more

August 28, 2019

Telix Enters Collaboration with DKFZ Researchers to Develop Image-Guided Surgery

News

Telix Pharmaceuticals has established a collaboration agreement with a team of researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, or DKFZ) to develop an innovative image-guided surgery for men ... Read more

August 26, 2019

Request for Xtandi to Treat Metastatic Hormone-sensitive Prostate Cancer Before FDA

News

The U.S. Food and Drug Administration (FDA) has agreed to review Astellas Pharma and Pfizer‘s application for Xtandi (enzalutamide), requesting its approved use be expanded to include men whose metastatic prostate ... Read more

August 22, 2019

PSMA-targeted Therapies Work Best in Tumors with Mutations in DNA Repair Genes, Study Suggests

News

Tumors with large numbers of prostate cancer cells with mutations in DNA repair genes are easier to target using prostate-specific membrane antigen (PSMA) therapies, and patients with these tumors are more ... Read more

August 21, 2019

Myriad to Seek FDA Approval of Diagnostic Test to Determine Lynparza Eligibility for mCRPC Patients

News

Myriad Genetics is filing an application with the U.S. Food and Drug Administration requesting the approval of its BRACAnalysis CDx — which identifies inherited BRCA mutations — as a companion ... Read more

August 19, 2019

Phase 1 Trial Enrolling Advanced, Castration-resistent Patients to Test Triple Immunotherapy Combo

News

A Phase 1 trial is enrolling people with metastatic castration-resistant prostate cancer (mCRPC) to test Inovio Pharmaceutical‘s immunotherapy INO-5151 in combination with two other immunotherapies — Celldex’s CDX-301 and Bristol-Myers Squibb’s Opdivo (nivolumab). ... Read more